Bladder Cancer VL

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

Details
With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...

Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan

Details
Yair Lotan joins Ashish Kamat in a slide presentation discussion on urine markers for hematuria and bladder cancer. Dr. Lotan overviews a number of recently published papers and new studies in this space. He highlights limitations and challenges with cytology, the current role of markers and where they stand in clinical use, and urinary markers that are available as well as in development for pati...

Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak

Details
Subtypes in non-muscle-invasive bladder cancer are not well-defined, whereas the molecular landscape of muscle-invasive bladder cancer is relatively well-established. During the optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Eugene Pietzak, MD, discussed the molecular landscape...

Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer - Lars Dyrskjøt

Details
In this conversation with Ashish Kamat, Lars Dyrskjøt, an expert in the field of molecular markers and personalized medicine speaks about circulating tumor DNA and the potential as a tumor for guiding treatment decisions in bladder cancer. Cell-free DNA in the blood has a half-life of less than two hours, so it makes it possible to use it as a biomarker of the direct tumor burden and hence the det...

Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner

Details
Bernard Bochner joins Ashish Kamat in this discussion discussing the advancements throughout 2020 in muscle-invasive non-metastatic bladder cancer. It would be impossible to discuss the year without mentioning the impact of COVID-19. There are some diseases that can withstand treatment delay, but muscle-invasive bladder cancer is not one of those tumors. These challenges pushed the bladder cancer...

EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2020 Update - Marek Babjuk

Details
The European Association of Urology (EAU) published its updated guideline recommendations for non-muscle invasive bladder cancer (NMIBC) in 2020. The updated EAU Guidelines stratify NMIBC into low, intermediate, and high risk for treatment options. In this conversations with Ashish Kamat, MD, MBBS, Marko Babjuk, MD, Ph.D., overviews the 2020 updated guidelines highlighting changes in the guideline...

DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt

Details
Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...

Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar

Details
In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse

Details
Ashish Kamat welcomes Karen Sachse, a patient advocate for the Bladder Cancer Advocacy Network (BCAN) who shares her perspective on non muscle-invasive bladder cancer, the various trials that are ongoing, and the future of various studies. As a bladder cancer survivor diagnosed in 2010 at age 54 with high grade non-muscle invasive bladder cancer, she is disease-free since 2014. Biographies: Karen...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...
email news signup